$15.42
0.030.19%
Last update: 8:34 AM
15 minutes delayed
Sabra Health Care REIT
SBRANASDAQ
want to know what
the Bulls & Bears Say?
Sabra Health Care REIT (NASDAQ:SBRA) Stock, Analyst Ratings, Price Targets, Forecasts
Sabra Health Care REIT Inc has a consensus price target of $12.53 based on the ratings of 33 analysis. The 3 most-recent analyst ratings were released by Truist Securities, Scotiabank, and Deutsche Bank on June 27, 2024, May 15, 2024, and January 30, 2024, respectively. With an average price target of $17.33 between Truist Securities, Scotiabank, and Deutsche Bank, there's an implied 12.41% upside for Sabra Health Care REIT Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Scotiabank
Deutsche Bank
Mizuho
Stifel
1calculated from analyst ratings
Analyst Ratings for Sabra Health Care REIT
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 3.76% | Truist Securities | Michael Lewis | $15 → $16 | Maintains | Buy | Get Alert |
| 05/15/2024 | Buy Now | -2.72% | Scotiabank | Nicholas Yulico | $14 → $15 | Maintains | Sector Perform | Get Alert |
| 01/30/2024 | Buy Now | 36.19% | Deutsche Bank | Omotayo Okusanya | → $21 | Initiates | → Buy | Get Alert |
| 01/03/2024 | Buy Now | 10.25% | Mizuho | Vikram Malhotra | $15 → $17 | Maintains | Buy | Get Alert |
| 11/07/2023 | Buy Now | 3.76% | Stifel | Stephen Manaker | $14 → $16 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | -2.72% | Wells Fargo | Connor Siversky | $13 → $15 | Maintains | Equal-Weight | Get Alert |
| 10/17/2023 | Buy Now | 3.76% | BMO Capital | John Kim | → $16 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/16/2023 | Buy Now | -2.72% | Wells Fargo | Connor Siversky | → $15 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 10/10/2023 | Buy Now | — | B of A Securities | Joshua Dennerlein | — | Upgrade | Neutral → Buy | Get Alert |
| 10/03/2023 | Buy Now | 3.76% | Wedbush | Richard Anderson | → $16 | Initiates | → Outperform | Get Alert |
| 09/20/2023 | Buy Now | -2.72% | Jefferies | Jonathan Petersen | $11 → $15 | Upgrade | Hold → Buy | Get Alert |
| 08/11/2023 | Buy Now | -9.21% | B of A Securities | Joshua Dennerlein | $11 → $14 | Upgrade | Underperform → Neutral | Get Alert |
| 07/27/2023 | Buy Now | -15.69% | Berenberg | Tao Qiu | → $13 | Initiates | → Hold | Get Alert |
| 07/14/2023 | Buy Now | -18.94% | Citigroup | Nicholas Joseph | $11 → $12.5 | Maintains | Neutral | Get Alert |
| 04/25/2023 | Buy Now | -15.69% | Barclays | Steve Valiquette | $15 → $13 | Maintains | Equal-Weight | Get Alert |
| 04/20/2023 | Buy Now | -28.66% | Wells Fargo | Connor Siversky | → $11 | Initiates | → Underweight | Get Alert |
| 04/19/2023 | Buy Now | -28.66% | Wells Fargo | Connor Siversky | → $11 | Initiates | → Underweight | Get Alert |
| 04/12/2023 | Buy Now | -15.69% | Credit Suisse | Omotayo Okusanya | → $13 | Reiterates | → Neutral | Get Alert |
| 03/29/2023 | Buy Now | -15.69% | Truist Securities | Michael Lewis | $14 → $13 | Maintains | Buy | Get Alert |
| 03/28/2023 | Buy Now | -31.91% | Citigroup | Nicholas Joseph | $13 → $10.5 | Maintains | Neutral | Get Alert |
| 12/13/2022 | Buy Now | — | JMP Securities | Aaron Hecht | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 11/14/2022 | Buy Now | -15.69% | B of A Securities | Joshua Dennerlein | $15 → $13 | Downgrade | Neutral → Underperform | Get Alert |
| 10/10/2022 | Buy Now | -15.69% | Baird | David Rodgers | → $13 | Downgrade | Outperform → Neutral | Get Alert |
| 06/30/2022 | Buy Now | -9.21% | Jefferies | Jonathan Petersen | $15 → $14 | Downgrade | Buy → Hold | Get Alert |
| 05/25/2022 | Buy Now | -2.72% | Mizuho | Vikram Malhotra | $16 → $15 | Upgrade | Neutral → Buy | Get Alert |
| 04/18/2022 | Buy Now | -9.21% | Barclays | Steve Valiquette | $16 → $14 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/04/2022 | Buy Now | -2.72% | Credit Suisse | Omotayo Okusanya | $14 → $15 | Maintains | Neutral | Get Alert |
| 03/11/2022 | Buy Now | -2.72% | B of A Securities | Joshua Dennerlein | → $15 | Upgrade | Underperform → Neutral | Get Alert |
| 02/23/2022 | Buy Now | 16.73% | Stifel | Stephen Manaker | $21 → $18 | Maintains | Buy | Get Alert |
| 02/18/2022 | Buy Now | — | Keybanc | Jordan Sadler | — | Initiates | → Sector Weight | Get Alert |
| 02/01/2022 | Buy Now | -9.21% | Credit Suisse | Tayo Okusanya | → $14 | Initiates | → Neutral | Get Alert |
| 09/30/2021 | Buy Now | 16.73% | Truist Securities | Michael Lewis | — | Upgrade | Hold → Buy | Get Alert |
| 09/13/2021 | Buy Now | 29.7% | JMP Securities | Aaron Hecht | — | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for Sabra Health Care REIT (SBRA) stock?
The latest price target for Sabra Health Care REIT (NASDAQ:SBRA) was reported by Truist Securities on June 27, 2024. The analyst firm set a price target for $16.00 expecting SBRA to rise to within 12 months (a possible 3.76% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?
The latest analyst rating for Sabra Health Care REIT (NASDAQ:SBRA) was provided by Truist Securities, and Sabra Health Care REIT maintained their buy rating.
When was the last upgrade for Sabra Health Care REIT (SBRA)?
The last upgrade for Sabra Health Care REIT Inc happened on October 16, 2023 when Wells Fargo raised their price target to $15. Wells Fargo previously had an underweight for Sabra Health Care REIT Inc.
When was the last downgrade for Sabra Health Care REIT (SBRA)?
The last downgrade for Sabra Health Care REIT Inc happened on October 17, 2023 when BMO Capital changed their price target from N/A to $16 for Sabra Health Care REIT Inc.
When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?
While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a maintained with a price target of $15.00 to $16.00. The current price Sabra Health Care REIT (SBRA) is trading at is $15.42, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.